

Jean Michel Pawlotsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7537772/publications.pdf>

Version: 2024-02-01

73
papers

7,463
citations

126907
33
h-index

79698
73
g-index

76
all docs

76
docs citations

76
times ranked

11104
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology, 2018, 69, 461-511.	3.7	1,489
2	EASL recommendations on treatment of hepatitis C: Final update of the series†. Journal of Hepatology, 2020, 73, 1170-1218.	3.7	671
3	New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges. Gastroenterology, 2014, 146, 1176-1192.	1.3	458
4	Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology, 2016, 151, 70-86.	1.3	457
5	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ, The, 2020, 369, m1844.	6.0	355
6	Chronic hepatitis B virus infection. Lancet, The, 2018, 392, 2313-2324.	13.7	351
7	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology, 2016, 64, 2038-2046.	7.3	343
8	Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology, 2011, 53, 1742-1751.	7.3	285
9	Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell, 2021, 184, 1201-1213.e14.	28.9	260
10	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. Gastroenterology, 2014, 147, 132-142.e4.	1.3	232
11	Impact of COVID-19 on global HCV elimination efforts. Journal of Hepatology, 2021, 74, 31-36.	3.7	189
12	Interferon Resistance of Hepatitis C Virus Genotype 1b: Relationship to Nonstructural 5A Gene Quasispecies Mutations. Journal of Virology, 1998, 72, 2795-2805.	3.4	189
13	NS5A inhibitors in the treatment of hepatitis C. Journal of Hepatology, 2013, 59, 375-382.	3.7	172
14	Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides. Hepatology, 2020, 72, 2000-2013.	7.3	158
15	New Virologic Tools for Management of Chronic Hepatitis B and C. Gastroenterology, 2012, 142, 1303-1313.e1.	1.3	109
16	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity, 2021, 54, 2893-2907.e5.	14.3	107
17	Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. Hepatology, 2017, 66, 1826-1841.	7.3	94
18	Dynamics of Hepatitis B Virus Resistance to Lamivudine. Journal of Virology, 2006, 80, 643-653.	3.4	88

#	ARTICLE	IF	CITATIONS
19	Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. <i>Liver International</i> , 2021, 41, 456-463.	3.9	81
20	Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. <i>Hepatology</i> , 2019, 69, 513-523.	7.3	79
21	Evolution of the Hepatitis C Virus Second Envelope Protein Hypervariable Region in Chronically Infected Patients Receiving Alpha Interferon Therapy. <i>Journal of Virology</i> , 1999, 73, 6490-6499.	3.4	73
22	Tissue damage induces a conserved stress response that initiates quiescent muscle stem cell activation. <i>Cell Stem Cell</i> , 2021, 28, 1125-1135.e7.	11.1	72
23	Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. <i>Nature Communications</i> , 2016, 7, 12777.	12.8	67
24	Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. <i>Hepatology</i> , 2016, 63, 1809-1816.	7.3	60
25	Small-Molecule Inhibitors of Cyclophilins Block Opening of the Mitochondrial Permeability Transition Pore and Protect Mice From Hepatic Ischemia/Reperfusion Injury. <i>Gastroenterology</i> , 2019, 157, 1368-1382.	1.3	60
26	Performance of Version 2.0 of the Cobas AmpliPrep/Cobas TaqMan Real-Time PCR Assay for Hepatitis B Virus DNA Quantification. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3641-3647.	3.9	58
27	Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	57
28	Hepatitis C Treatment: The Data Flood Goes on—An Update From the Liver Meeting 2014. <i>Gastroenterology</i> , 2015, 148, 468-479.	1.3	48
29	COVID-19 and the liver-related deaths to come. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 523-525.	17.8	48
30	Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2015, 62, 1013-1023.	7.3	46
31	Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. <i>Hepatology</i> , 2019, 70, 771-787.	7.3	46
32	Virologic Tools for HCV Drug Resistance Testing. <i>Viruses</i> , 2015, 7, 6346-6359.	3.3	43
33	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. <i>Immunity</i> , 2022, 55, 1096-1104.e4.	14.3	42
34	Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. <i>Journal of Hepatology</i> , 2022, 77, 116-127.	3.7	40
35	BNT162b2 Messenger RNA Vaccination Did Not Prevent an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 Variant 501Y.V2 in an Elderly Nursing Home but Reduced Transmission and Disease Severity. <i>Clinical Infectious Diseases</i> , 2022, 74, 517-520.	5.8	36
36	Sequence and Phenotypic Analysis for Resistance Monitoring in Hepatitis C Virus Drug Development: Recommendations From the HCV DRAG. <i>Gastroenterology</i> , 2011, 140, 755-760.e12.	1.3	34

#	ARTICLE	IF	CITATIONS
37	Direct-Acting Antiviral Agents and the Path to Interferon Independence. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 728-737.	4.4	34
38	Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. <i>Seminars in Liver Disease</i> , 2019, 39, 354-368.	3.6	30
39	Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009416.	4.7	30
40	SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients. <i>Intensive Care Medicine</i> , 2020, 46, 1781-1783.	8.2	29
41	Hepatitis C Drugs: Is Next Generation the Last Generation?. <i>Gastroenterology</i> , 2016, 151, 587-590.	1.3	24
42	Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice. <i>Journal of Biological Chemistry</i> , 2017, 292, 12860-12873.	3.4	20
43	COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. <i>Clinical Infectious Diseases</i> , 2020, 71, 2191-2194.	5.8	20
44	HCV variability, the immune system and resistance to antiviral drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 383-385.	17.8	18
45	HCV RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals. <i>Antiviral Therapy</i> , 2015, 20, 177-183.	1.0	17
46	DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world?. <i>Journal of Hepatology</i> , 2019, 71, 1070-1072.	3.7	17
47	The New Aptima HCV Quant Dx Real-time TMA Assay Accurately Quantifies Hepatitis C Virus Genotype 1-6 RNA. <i>Journal of Clinical Virology</i> , 2017, 91, 5-11.	3.1	16
48	Characterization of V36C, a Novel Amino Acid Substitution Conferring Hepatitis C Virus (HCV) Resistance to Telaprevir, a Potent Peptidomimetic Inhibitor of HCV Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2681-2683.	3.2	15
49	The New Aptima HBV Quant Real-Time TMA Assay Accurately Quantifies Hepatitis B Virus DNA from Genotypes A to F. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1211-1219.	3.9	14
50	Evaluation of the Xpert HBV Viral Load for hepatitis B virus molecular testing. <i>Journal of Clinical Virology</i> , 2020, 129, 104481.	3.1	14
51	The end of the hepatitis C burden: Really?. <i>Hepatology</i> , 2016, 64, 1404-1407.	7.3	13
52	Prospective Comparison Between Shotgun Metagenomics and Sanger Sequencing of the 16S rRNA Gene for the Etiological Diagnosis of Infections. <i>Frontiers in Microbiology</i> , 2022, 13, 761873.	3.5	13
53	Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	12
54	Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2022, 74, 707-710.	5.8	10

#	ARTICLE	IF	CITATIONS
55	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. EBioMedicine, 2022, 77, 103934.	6.1	10
56	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports, 2022, 4, 100462.	4.9	10
57	Evaluation of a new random-access HBV DNA molecular assay: The VERIS HBV assay. Journal of Clinical Virology, 2017, 92, 69-74.	3.1	9
58	A Phenyl-Pyrrolidine Derivative Reveals a Dual Inhibition Mechanism of Myocardial Mitochondrial Permeability Transition Pore, Which Is Limited by Its Myocardial Distribution. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 348-357.	2.5	9
59	Fatal encephalitis caused by Newcastle disease virus in a child. Acta Neuropathologica, 2021, 142, 605-608.	7.7	9
60	Variable In Vivo Hepatitis D Virus (HDV) RNA Editing Rates According to the HDV Genotype. Viruses, 2021, 13, 1572.	3.3	9
61	Microdiversity of <i>Enterococcus faecalis</i> isolates in cases of infective endocarditis: selection of non-synonymous mutations and large deletions is associated with phenotypic modifications. Emerging Microbes and Infections, 2021, 10, 929-938.	6.5	9
62	Performance of a high-throughput, automated enzyme immunoassay for the detection of SARS-CoV-2 antigen, including in viral variants of concern: Implications for clinical use. Journal of Clinical Virology, 2022, 146, 105048.	3.1	7
63	SHARED: An International Collaboration to Unravel Hepatitis C Resistance. Viruses, 2021, 13, 1580.	3.3	6
64	Performance of 22 Rapid Lateral Flow Tests for SARS-CoV-2 Antigen Detection and Influence of Variants of Concern: Implications for Clinical Use. Microbiology Spectrum, 2022, 10, .	3.0	6
65	Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes. Alimentary Pharmacology and Therapeutics, 2020, 52, 1583-1591.	3.7	5
66	Case Report: Cerebral Nocardiosis Caused by Nocardia cyriacigeorgica Detected by Metagenomics in an Apparently Immunocompetent Patient. Frontiers in Immunology, 2022, 13, 719124.	4.8	5
67	HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. PLoS ONE, 2015, 10, e0127816.	2.5	3
68	Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About eight cases resolved by a sequencing method. Journal of Medical Virology, 2018, 90, 1352-1357.	5.0	3
69	Differential anti-S antibody titers in vaccinated residents during an outbreak of SARS-CoV-2 variant B.1.351 (Î2) in an elderly nursing home. Clinical Infectious Diseases, 2021, , .	5.8	3
70	Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection. Clinical Liver Disease, 2012, 1, 58-61.	2.1	2
71	Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas® HBV Test for Use on the Cobas® 4800 System. Microorganisms, 2021, 9, 573.	3.6	2
72	Alinity m, a Random-Access System, for Hepatitis B Virus DNA Quantification in Plasma and Whole Blood Collected on Dried Blood Spots. MSphere, 2022, 7, e0008222.	2.9	1

#	ARTICLE	IF	CITATIONS
73	Presentation and outcomes of SARS-CoV-2 Omicron variant infection in haemodialysis patients. CKJ: Clinical Kidney Journal, 2022, 15, 1785-1788.	2.9	1